Diabetic eye screening and glucagon-like peptide agonists: guidance
Diabetic eye screening: no extra screening is currently advised for rapid glucose improvement, including with GLP-1/GIP agonists, while evidence is reviewed.
Category Prescribing & medicines
Showing: Guidance Everything, including news and events
Topics:Collective action & GPCContracts & fundingPCNs & neighbourhoodsVaccinations & screeningPrescribing & medicinesReferrals & hospital servicesPublic healthIT, data & cyber securityWorkforce & employmentCQC, regulation & governancePCSE & patient registrationFees & non-NHS workPremises & estatesWellbeing & supportBLMC news
GPC letter on dispensing practices and EPS costs
Deal ensures continued access to inclisiran (Leqvio)
Reminder that NHS England's renewed deal with Novartis keeps inclisiran available within the lipid management pathway.